RBC Capital Maintains Outperform on Biogen, Raises Price Target to $242

Benzinga Newsdesk www.benzinga.com Positive 85.7%

Neg 0% Neu 0% Pos 85.7%

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $227 to $242.